Announcement of the financial reports for the
second quarter of 2022 has been approved by
the board of directors
Date of events
2022/08/01
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/01
2.Date of the audit committee approved:2022/08/01
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):368,610
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):114,567
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):69,501
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):128,855
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):103,064
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):103,064
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):2.57
11.Total assets end of the period (thousand NTD):2,581,750
12.Total liabilities end of the period
(thousand NTD):732,035
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,849,715
14.Any other matters that need to be specified:None
Attachments
Original Link
Original Document
Permalink
Disclaimer
SYN-Tech Chem & Pharm Co. Ltd. published this content on 01 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 01 August 2022 09:43:05 UTC.
SYN-TECH Chem. & Pharm. Co., Ltd. is a Taiwan-based company principally engaged in the production, processing and distribution of active pharmaceutical ingredients (APIs). The Companyâs main products consist of muscle relaxants, local anesthetics, cardiovascular agents, antipyretics, analgesics and anti-inflammatory drugs, antimicrobials, spirit stabilizers, intermediates and others. It is also engaged in the pharmaceutical agency business. The Company distributes its products within Taiwan market and to overseas markets, including Asia, Europe, the Americas and Africa.